Eosinophil prostaglandin d2 receptor assays
CA 2454347 A1 · Owner: Merck Frosst Canada & Co./Merck Frosst Canada & Cie · Inventors: Nantel, Francois; Gervais, Francois
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention identifies different activities mediated by eosinophil PGD2 receptors and features methods measuring the ability of a compound to modulate such activities. Activities mediated by eosinophil PGD2 receptors include those associated with CRHT2 and those associated with the DP receptor. Activities identified herein as associated with eosinophil CRHT2 include a change in cell morphology, degranulation and a specific chemokinetic effect. , Activities identified herein as associated with the eosinophil DP receptor include resistance to apoptosis.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 17, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 17, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 17, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.